Product Description
Escitalopram is an antidepressant medication that works in the brain. It is approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Escitalopram-(Lexapro))
Mechanisms of Action: SSR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Depressive Disorder | Depressive Disorder, Major
Known Adverse Events: Insomnia
Company: Lundbeck
Company Location: DENMARK G7 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Depressive Disorder, Major
Phase 2: Alzheimer Disease|Cerebrovascular Disorders|Parkinson's Disease
Phase 1: Insomnia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EAST | P2 |
Not yet recruiting |
Cerebrovascular Disorders|Alzheimer Disease|Parkinson's Disease |
2025-09-01 |
|
| YZJ-1139-1-14 | P1 |
Active, not recruiting |
Insomnia |
2024-09-18 |
|
| JapicCTI-194585 | P3 |
Active |
Depressive Disorder, Major |
2022-12-31 |
|
| jRCT2080224520 | P3 |
Completed |
Depressive Disorder, Major |
2022-12-31 |